Eli Lilly Shifts Portfolio Focus, Boosts Outlook
Strong Quarter Signals Strategic Pivots Board a runaway train, folks, 'cause Eli Lilly (NYSE:LLY) is steaming ahead with third-quarter results that'll make any investor sit up and take notice. Revenue's up 39% to a hearty $24.4 billion, with Mounjaro and Zepbound doing some serious lifting. This ain't just small potatoes; it's full-on farm territory. Financial Peaks and...
Continue Reading